# Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer

> **NCT07634094** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Kalinski, Pawel, MD, PhD** · enrollment: 28 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Cisplatin
- **DRUG:** Bioferon
- **DRUG:** Rintatolimod
- **BIOLOGICAL:** αDC1 Vaccine
- **DRUG:** Pembrolizumab
- **DRUG:** Celecoxib
- **PROCEDURE:** Debulking Procedure

## Key facts

- **NCT ID:** NCT07634094
- **Lead sponsor:** Kalinski, Pawel, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2028-08
- **Final completion:** 2029-08
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-06-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07634094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07634094, "Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07634094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*